Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05693766
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Invasive Mammary Carcinoma
- Metastatic Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sonya Reid
- Last updated on ClinicalTrials.gov
- January 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama Birmingham · Birmingham, AL
Tennessee · 1
- Vanderbilt University/Ingram Cancer Center · Nashville, TN
Texas · 1
- UT Southwestern Medical Center · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.